PureTech Health plc (LON:PRTC)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 319.36M -3.6% |
| Revenue (ttm) | 3.46M -3.5% |
| Net Income | -81.54M |
| EPS | -0.34 |
| Shares Out | 243.42M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 22,094 |
| Open | 131.11 |
| Previous Close | 131.20 |
| Day's Range | 129.60 - 134.40 |
| 52-Week Range | 104.71 - 148.00 |
| Beta | 0.81 |
| Analysts | Strong Buy |
| Price Target | 383.96 (+195.81%) |
| Earnings Date | Aug 28, 2026 |
About PureTech Health
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential to establish a new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases and LYT-200, a fully human IgG4 monoclonal antibody. The company also develops SPT-300, a Glyphed oral prodrug of allopregnanolone for the treatment of anxious depression; and delivers transformati... [Read more]
Analyst Summary
According to 3 analysts, the average rating for PRTC stock is "Strong Buy." The 12-month stock price target is 384p, which is an increase of 195.81% from the latest price.
News
PureTech Health: Results of Annual General Meeting
BOSTON--(BUSINESS WIRE)--PureTech Health: Results of Annual General Meeting.
PureTech Health Earnings Call Transcript: H2 2025
Refined strategy emphasizes operational efficiency, early spin-outs, and disciplined capital allocation. Cash runway extends through 2028, with major progress in Celea and Gallop clinical programs and a focus on returning capital to shareholders after significant inflows.
PureTech Health Annual report: H2 2025
PureTech Health has published its H2 2025 annual report on April 29, 2026.
PureTech Health Annual report: H2 2025
PureTech Health has published its H2 2025 annual report on April 29, 2026.
PureTech Health Annual report: H2 2025
PureTech Health has published its H2 2025 annual report on April 29, 2026.
PureTech Health to delist American depositary shares from Nasdaq
PureTech Health (PRTC) announced that it has notified Nasdaq of its intention to voluntarily delist its American depositary shares, each representing the right to receive 10 ordinary shares of the…
PureTech Health announces data from Phase 1b trial of LYT-200
PureTech Health (PRTC) announced positive topline data from the completed Phase 1b clinical trial of LYT-200, a fully human anti-galectin-9 monoclonal antibody, in heavily pretreated patients with rel...
PureTech Health announces publication of Phase 2b ELEVATE IPF trial results
PureTech Health (PRTC) announced the publication of results from the Phase 2b ELEVATE IPF trial of deupirfenidone for the potential treatment of idiopathic pulmonary fibrosis in The American Journal o...
PureTech founded Seaport announces topline results from GlyphAgo trial
PureTech Health (PRTC) notes that its Founded Entity, Seaport Therapeutics, announced topline data from portions of its ongoing Phase 1 proof-of-concept clinical trial evaluating GlyphAgo. GlyphAgo is...
PureTech Health Transcript: Leerink Global Healthcare Conference 2026
The conference highlighted a robust hub-and-spoke model driving innovation and value through spin-outs, with strong clinical progress in IPF and oncology. Deupirfenidone is poised for a pivotal phase 3 trial, and the company remains self-funded with significant future milestones expected.
PureTech Health announces orphan drug designation for Deupirfenidone in IPF
PureTech Health (PRTC) announced that the U.S. Food and Drug Administration and European Commission have granted Orphan Drug Designation to deupirfenidone for the treatment of idiopathic pulmonary fib...
PureTech Health Transcript: 44th Annual J.P. Morgan Healthcare Conference
A diversified hub-and-spoke model drives innovation and financial returns by spinning out de-risked drug programs, with a strong track record of clinical and commercial success. Key assets Celea and Gallop are advancing to pivotal trials, while the company remains self-funded and focused on efficient capital allocation.
PureTech Health appoints Robert Lyne as CEO
PureTech Health (PRTC) announces that the board of directors has appointed Robert Lyne as CEO, and as a member of the board of directors, effective immediately. Lyne has served as…
PureTech Health completes LYT-100 End-of-Phase 2 meeting with FDA
PureTech Health (PRTC) announced the completion of the End-of-Phase 2 meeting with the FDA regarding the development of deupirfenidone, or LYT-100, for the treatment of idiopathic pulmonary fibrosis. ...
PureTech Health presents new analyses from ELEVATE IPF trial
PureTech Health (PRTC) announced the presentation of new analyses from the Phase 2b ELEVATE IPF trial of deupirfenidone for the treatment of idiopathic pulmonary fibrosis. The data show that the…
PureTech Health says Seaport Therapeutics doses first patient in GlyphAgo study
PureTech Health (PRTC) noted that its founded entity, Seaport Therapeutics, announced that the first participant has been dosed in the Phase 1 study of GlyphAgo.
PureTech Health Earnings Call Transcript: H1 2025
Strong H1 2025 performance with $320M cash, reduced expenses, and focus on three core entities—Seaport, Gallop, and Celea. Key clinical milestones and external financings are expected to extend runway and drive value, with major data readouts and Phase III trial initiations ahead.
PureTech Health Quarterly report: H1 2025
PureTech Health has published its H1 2025 quarterly earnings report on August 28, 2025.
PureTech says Vedanta ulcerative colitis study missed endpoint
PureTech Health (PRTC), noted that its Founded Entity, Vedanta Biosciences, announced that its candidate VE202 did not meet the primary endpoint in the Phase 2 COLLECTiVE202 study for the treatment…
PureTech Health doses first patient in BUOY-1 study
PureTech Health (PRTC) announced that the first patient has been dosed in the Phase 2b BUOY-1 study of GlyphAllo SPT-300 or Glyph Allopregnanolone in major depressive disorder with or without…
PureTech Health CEO Bharatt Chowrira steps down
PureTech Health (PRTC) announced that Bharatt Chowrira has stepped down from his role as CEO and as a member of the board of directors. The board of directors has appointed…
PureTech Health says Raju Kucherlapati steps down as board chair
PureTech Health (PRTC) announced that Raju Kucherlapati, PhD, has stepped down from his role as a member and Chair of the Board of Directors. “Raju has been an integral part…
PureTech Health founded entity Vor Bio enters license agreement with RemeGen
PureTech Health (PRTC) noted that its founded entity, Vor Bio (VOR) and RemeGen announced entry into an exclusive license agreement granting Vor Bio global rights to develop and commercialize telitaci...
PureTech Health Transcript: Jefferies Global Healthcare Conference 2025
A diversified R&D model has driven strong financial performance and clinical success, highlighted by the lead IPF program deupirfenidone, which demonstrated robust efficacy and durability in trials and is advancing to phase III. The company’s pipeline, including CNS and oncology assets, is supported by a self-funding structure and significant milestone revenues.
PureTech Health presents deupirfenidone data at ATS conference
PureTech Health (PRTC) delivered a late-breaking, oral presentation at the 2025 American Thoracic Society international conference in San Francisco. The presentation provided further insights into the...